Starget Pharma

Executive Summary

Starget Pharma is an Israeli biotech leveraging an AI-driven peptide backbone dynamics platform to design Smart Targeted Radioligands (STRs) for precision oncology. The company's technology aims to overcome limitations of current radiopharmaceuticals by optimizing peptide stability and target binding, enabling delivery of high-energy radiation to difficult-to-treat tumors while minimizing off-target toxicity. Founded in 2020, Starget is in the preclinical stage, focusing on developing a pipeline of peptide-based radiopharmaceuticals for various solid tumors. The AI platform accelerates the discovery and optimization of lead candidates, potentially reducing development timelines. Starget's approach addresses key challenges in radiopharmaceutical development, such as tumor heterogeneity and resistance, by enabling precise targeting. With its focus on unmet medical needs in oncology, particularly for hard-to-treat tumors, Starget Pharma represents a promising early-stage player in the rapidly growing radiopharmaceutical sector. The company is based in Rehovot, Israel, and continues to advance its lead programs toward clinical development.

Upcoming Catalysts (preview)

• Q2 2027IND/CTA filing for lead candidate30% success
• Q4 2026Presentation of in vivo efficacy data at major oncology conference70% success
• Q3 2026Potential partnership or licensing deal20% success